Key facts
- WhiteSwell’s last known valuation is $71.5M (Dec 2018).
- It has raised $30.0M; the latest was Later Stage VC in Feb 2025.
- Notable investors include Enterprise Ireland, RA Capital Management, Western Development Commission, VI Ventures, Abiomed — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for WhiteSwell
- ·The full record, as it builds
Funding rounds
No funding rounds for WhiteSwell are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About WhiteSwell
Operator of a science-driven company intended to improve the treatment of acute decompensated heart failure by leveraging the lymphatic system. The company provides a medical device to create a low-pressure zone at the thoracic duct outlet to reduce resistance to lymphatic drainage and improve clinical outcomes for ADHF patients, enabling the healthcare industry to address the unmet need for effective and safe treatment options for ADHF, a serious condition with high mortality rates.
- Sector
- Healthcare
- HQ
- Galway, Ireland
- Founded
- 2014
- Employees
- 40
- Website
- whiteswell.com/
- Ownership
- Privately Held (backing)
WhiteSwell doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in WhiteSwell shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on WhiteSwell in its N-PORT filings yet. We sweep new filings monthly.